Acorda Therapeutics (ACOR) Reports Q3 EPS of 28c
Get Alerts ACOR Hot Sheet
Price: $0.66 --0%
Revenue Growth %: +63.1%
Financial Fact:
Net sales: 128.51M
Today's EPS Names:
SFST, VLTO, CLIR, More
Revenue Growth %: +63.1%
Financial Fact:
Net sales: 128.51M
Today's EPS Names:
SFST, VLTO, CLIR, More
Join SI Premium – FREE
Acorda Therapeutics (NASDAQ: ACOR) reported Q3 EPS of $0.28, may not compare to the analyst estimate of $0.05. Revenue for the quarter came in at $106 million versus the consensus estimate of $94.7 million.
It raised full year 2014 guidance for AMPYRA net revenue from $328-$335 million to $345-$350 million
For earnings history and earnings-related data on Acorda Therapeutics (ACOR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lockheed Martin (LMT) Tops Q1 EPS by 53c, Beats on Revenue; Offers FY24 Guidance
- NVR, Inc. (NVR) Tops Q1 EPS by 1244c
- Spotify (SPOT) jumps 10% as Q1 revenue, gross margins beat Street's estimates
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!